Skip to main content

Published locations for RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients

User login

  • Reset your password
  • /content/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy-older-cll-patients
  • /fedprac/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy-older-cll
  • /hematologynews/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy
  • /jcso/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy-older-cll
  • /oncologypractice/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy
  • /fedprac/avaho/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy-older
  • /hematologynews/nhlhub/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained
  • /hematology-oncology/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained-efficacy
  • /b-cell-lymphoma-icymi/article/174222/cll/resonate-2-update-first-line-ibrutinib-has-sustained